

References

- Gregoratos G, Abrams J, Epstein AE, *et al.* ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). *Circulation* 2002;**106**:2145–2161.
- Antman EM, Anbe DT, Armstrong PW, *et al.* ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). *J Am Coll Cardiol* 2004;**44**:E1–211.
- Priori SG, Aliot E, Blomstrom-Lundqvist C, *et al.* Task Force on Sudden Cardiac Death of the European Society of Cardiology. *Eur Heart J* 2001;**22**:1374–1450.
- Priori SG, Aliot E, Blomstrom-Lundqvist C, *et al.* Update of the guidelines on sudden cardiac death of the European Society of Cardiology. *Eur Heart J* 2003;**24**:13–15.
- Swedberg K, Cleland J, Dargie H, *et al.* Executive summary of the guidelines for the diagnosis and treatment of chronic heart failure: the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. *Eur Heart J* 2005;**26**:1115–1140.
- Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *J Am Coll Cardiol* 2005;**46**:e1–82.
- Buxton AE. A report of the American College of Cardiology Task Force on Clinical Data Standards (Electrophysiology Writing Committee). Manuscript in preparation.
- Poole JE, Bardy GH, Sudden Cardiac Death. In: Zipes DP, Jalife J, eds. *Cardiac Electrophysiology: From Cell to Bedside*. 3rd edn. Philadelphia, PA: W.B. Saunders Company; 2000. p615–640.
- Bardy GH, Lee KL, Mark DB, *et al.* Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005;**352**:225–237.
- Gillum RF. Sudden coronary death in the United States: 1980–1985. *Circulation* 1989;**79**:756–765.
- Escobedo LG, Zack MM. Comparison of sudden and nonsudden coronary deaths in the United States. *Circulation* 1996;**93**:2033–2036.
- Zheng ZJ, Croft JB, Giles WH, *et al.* Sudden cardiac death in the United States, 1989 to 1998. *Circulation* 2001;**104**:2158–2163.
- Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980–2000. *JAMA* 2002;**288**:3008–3013.
- American Heart Association; Heart Disease and Stroke Statistics—2005 Update. 2004: Dallas, TX: American Heart Association, 2004
- Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. *Ann Intern Med* 1993;**119**:1187–1197.
- Kuller L, Lilienfeld A, Fisher R. An epidemiological study of sudden and unexpected deaths in adults. *Medicine (Baltimore)* 1967;**46**:341–361.
- de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, *et al.* Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. *J Am Coll Cardiol* 1997;**30**:1500–1505.
- Gillum RF. Geographic variation in sudden coronary death. *Am Heart J* 1990;**119**:380–389.
- Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. *J Cardiovasc Electrophysiol* 2001;**12**:369–381.
- Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. *N Engl J Med* 2001;**345**:1473–1482.
- Braunwald E. Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. *N Engl J Med* 1997;**337**:1360–1369.
- Myerburg RJ, Mitrani R, Interian A Jr., Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. *Circulation* 1998;**97**:1514–1521.
- Gibbons RJ, Balady GJ, Bricker JT, *et al.* ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *J Am Coll Cardiol* 2002;**40**:1531–1540.
- Jouven X, Zureik M, Desnos M, *et al.* Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. *N Engl J Med* 2000;**343**:826–833.
- Frolkis JP, Pothier CE, Blackstone EH, *et al.* Frequent ventricular ectopy after exercise as a predictor of death. *N Engl J Med* 2003;**348**:781–790.
- Huikuri HV, Makikallio TH, Raatikainen MJ, *et al.* Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death. *Circulation* 2003;**108**:110–115.
- Cheitlin MD, Alpert JS, Armstrong WF, *et al.* ACC/AHA guidelines for the Clinical Application of Echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. *Circulation* 1997;**95**:1686–1744.
- Cheitlin MD, Armstrong WF, Aurigemma GP, *et al.* ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). *J Am Coll Cardiol* 2003;**42**:954–970.
- Schiller NB, Shah PM, Crawford M, *et al.* Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards,

- Subcommittee on Quantitation of Two-Dimensional Echocardiograms. *J Am Soc Echocardiogr* 1989;2:358-367.
29. Ross DL, Farre J, Bar FW, *et al.* Comprehensive clinical electrophysiologic studies in the investigation of documented or suspected tachycardias. Time, staff, problems and costs. *Circulation* 1980;61:1010-1016.
30. Freedman RA, Swerdlow CD, Soderholm-Difatte V, *et al.* Prognostic significance of arrhythmia inducibility or noninducibility at initial electrophysiologic study in survivors of cardiac arrest. *Am J Cardiol* 1988;61:578-582.
31. Wilber DJ, Garan H, Finkelstein D, *et al.* Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome. *N Engl J Med* 1988;318:19-24.
32. Mittal S, Iwai S, Stein KM, *et al.* Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era. *J Am Coll Cardiol* 1999;34:1082-1089.
33. Gurevitz O, Viskin S, Glikson M, *et al.* Long-term prognosis of inducible ventricular flutter: not an innocent finding. *Am Heart J* 2004;147:649-654.
34. Viskin S, Justo D, Halkin A, *et al.* Long QT syndrome caused by noncardiac drugs. *Prog Cardiovasc Dis* 2003;45:415-427.
35. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. *J Clin Pharmacol* 1984;24:129-147.
36. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. *Circulation* 1991;84:1831-1851.
37. Reiter MJ, Reiffel JA. Importance of beta blockade in the therapy of serious ventricular arrhythmias. *Am J Cardiol* 1998;82:91-191.
38. Ellison KE, Hafley GE, Hickey K, *et al.* Effect of beta-blocking therapy on outcome in the Multicenter Unsustained Tachycardia Trial (MUSTT). *Circulation* 2002;106:2694-2699.
39. Connolly SJ. Meta-analysis of antiarrhythmic drug trials. *Am J Cardiol* 1999;84:90R-93R.
40. Steinberg JS, Martins J, Sadanandan S, *et al.* Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. *Am Heart J* 2001;142:520-529.
41. Farre J, Romero J, Rubio JM, *et al.* Amiodarone and 'primary' prevention of sudden death: critical review of a decade of clinical trials. *Am J Cardiol* 1999;83:55D-63D.
42. Cleland JG, Ghosh J, Freemantle N, *et al.* Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. *Eur J Heart Fail* 2004;6:501-508.
43. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. *Lancet* 1997;350:1417-1424.
44. Janse MJ, Malik M, Camm AJ, *et al.* Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). *Eur Heart J* 1998;19:85-95.
45. Boutitie F, Boissel JP, Connolly SJ, *et al.* Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. *Circulation* 1999;99:2268-2275.
46. Pacifico A, Hohnloser SH, Williams JH, *et al.* Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. *N Engl J Med* 1999;340:1855-1862.
47. Moss AJ, Hall WJ, Cannom DS, *et al.* Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med* 1996;335:1933-1940.
48. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. *N Engl J Med* 1997;337:1569-1575.
49. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. *N Engl J Med* 1997;337:1576-1583.
50. Buxton AE, Lee KL, Fisher JD, *et al.* A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med* 1999;341:1882-1890.
51. Moss AJ, Zareba W, Hall WJ, *et al.* Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;346:877-883.
52. Lee DS, Green LD, Liu PP, *et al.* Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. *J Am Coll Cardiol* 2003;41:1573-1582.
53. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. *Ann Intern Med* 2003;138:445-452.
54. Marenco JP, Wang PJ, Link MS, *et al.* Improving survival from sudden cardiac arrest: the role of the automated external defibrillator. *JAMA* 2001;285:1193-1200.
55. Priori SG, Bossaert LL, Chamberlain DA, *et al.* ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. *Eur Heart J* 2004;25:437-445.
56. Koster RW. Automatic external defibrillator: key link in the chain of survival. *J Cardiovasc Electrophysiol* 2002;13:S92-S95.
57. Valenzuela TD, Roe DJ, Nichol G, *et al.* Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. *N Engl J Med* 2000;343:1206-1209.
58. Caffrey SL, Willoughby PJ, Pepe PE, *et al.* Public use of automated external defibrillators. *N Engl J Med* 2002;347:1242-1247.
59. Silva RM, Mont L, Nava S, *et al.* Radiofrequency catheter ablation for arrhythmic storm in patients with an implantable cardioverter defibrillator. *Pacing Clin Electrophysiol* 2004;27:971-975.
60. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. *Circulation* 2003;108:3092-3096.
61. Pappone C, Santinelli V, Manguso F, *et al.* A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. *N Engl J Med* 2003;349:1803-1811.
62. Haissaguerre M, Shoda M, Jais P, *et al.* Mapping and ablation of idiopathic ventricular fibrillation. *Circulation* 2002;106:962-967.
63. Takemoto M, Yoshimura H, Ohba Y, *et al.* Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. *J Am Coll Cardiol* 2005;45:1259-1265.
64. Scheinman MM. NASPE survey on catheter ablation. *Pacing Clin Electrophysiol* 1995;18:1474-1478.
65. Twidale N, Hazlitt HA, Berbari EJ, *et al.* Late potentials are unaffected by radiofrequency catheter ablation in patients with ventricular tachycardia. *Pacing Clin Electrophysiol* 1994;17:157-165.
66. SippensGroenewegen A, Spektor H, van Hemel NM, *et al.* Localization of the site of origin of postinfarction ventricular tachycardia by endocardial pace mapping. Body surface mapping compared with the 12-lead electrocardiogram. *Circulation* 1993;88:2290-2306.
67. Morady F, Harvey M, Kalbfleisch SJ, *et al.* Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. *Circulation* 1993;87:363-372.
68. Stevenson WG, Khan H, Sager P, *et al.* Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. *Circulation* 1993;88:1647-1670.
69. Cohen TJ, Chien WW, Lurie KG, *et al.* Radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia: results and long-term follow-up. *J Am Coll Cardiol* 1991;18:1767-1773.
70. Tchou P, Jazayeri M, Denker S, *et al.* Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. *Circulation* 1988;78:246-257.
71. Nakagawa H, Beckman KJ, McClelland JH, *et al.* Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. *Circulation* 1993;88:2607-2617.
72. Page RL, Shenasa H, Evans JJ, *et al.* Radiofrequency catheter ablation of idiopathic recurrent ventricular tachycardia with right bundle branch block, left axis morphology. *Pacing Clin Electrophysiol* 1993;16:327-336.

73. Klein LS, Shih HT, Hackett FK, *et al.* Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. *Circulation* 1992;**85**:1666–1674.
74. Calkins H, Kalbfleisch SJ, el-Atassi R, *et al.* Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. *Am J Cardiol* 1993;**71**:827–833.
75. Kim YH, Sosa-Suarez G, Trouton TG, *et al.* Treatment of ventricular tachycardia by transcatheter radiofrequency ablation in patients with ischemic heart disease. *Circulation* 1994;**89**:1094–1102.
76. Coggins DL, Lee RJ, Sweeney J, *et al.* Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. *J Am Coll Cardiol* 1994;**23**:1333–1341.
77. Schwartz PJ, Priori SG, Cerrone M, *et al.* Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. *Circulation* 2004;**109**:1826–1833.
78. Carnendran L, Steinberg JS. Does an open infarct-related artery after myocardial infarction improve electrical stability? *Prog Cardiovasc Dis* 2000;**42**:439–454.
79. Hillis LD, Cigarroa JE, Lange RA. Late revascularization reduces mortality in survivors of myocardial infarction. *Cardiol Rev* 1999;**7**:144–148.
80. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 2005;**112**:IV1–IV203.
81. Nolan JP, Deakin CD, Soar J, *et al.* European Resuscitation Council Guidelines for Resuscitation 2005 Section 4. Adult advanced life support. *Resuscitation* 2005;**67**(Suppl 1):S39–S86.
82. Antman EM, Berlin JA. Declining incidence of ventricular fibrillation in myocardial infarction. Implications for the prophylactic use of lidocaine. *Circulation* 1992;**86**:764–773.
83. Behar S, Goldbourt U, Reicher-Reiss H, *et al.* Prognosis of acute myocardial infarction complicated by primary ventricular fibrillation. Principal Investigators of the SPRINT Study. *Am J Cardiol* 1990;**66**:1208–1211.
84. MacMahon S, Collins R, Peto R, *et al.* Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. *JAMA* 1988;**260**:1910–1916.
85. Higham PD, Adams PC, Murray A, *et al.* Plasma potassium, serum magnesium and ventricular fibrillation: a prospective study. *Q J Med* 1993;**86**:609–617.
86. Gorgels AP, van den Dool A, Hofs A, *et al.* Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. *Am J Cardiol* 1996;**78**:43–46.
87. Callans DJ, Marchlinski FE. Dissociation of termination and prevention of inducibility of sustained ventricular tachycardia with infusion of procainamide: evidence for distinct mechanisms. *J Am Coll Cardiol* 1992;**19**:111–117.
88. Sharma AD, Purves P, Yee R, *et al.* Hemodynamic effects of intravenous procainamide during ventricular tachycardia. *Am Heart J* 1990;**119**:1034–1041.
89. Nasir N Jr., Taylor A, Doyle TK, *et al.* Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction. *Am J Cardiol* 1994;**74**:1183–1186.
90. Lie KI, Wellens HJ, van Capelle FJ, *et al.* Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. *N Engl J Med* 1974;**291**:1324–1326.
91. Buxton AE, Marchlinski FE, Doherty JU, *et al.* Repetitive, monomorphic ventricular tachycardia: clinical and electrophysiologic characteristics in patients with and patients without organic heart disease. *Am J Cardiol* 1984;**54**:997–1002.
92. Rahilly GT, Prystowsky EN, Zipes DP, *et al.* Clinical and electrophysiologic findings in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram. *Am J Cardiol* 1982;**50**:459–468.
93. Lerman BB, Stein K, Engelstein ED, *et al.* Mechanism of repetitive monomorphic ventricular tachycardia. *Circulation* 1995;**92**:421–429.
94. Ouyang F, Fotuhi P, Ho SY, *et al.* Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. *J Am Coll Cardiol* 2002;**39**:500–508.
95. Sadanaga T, Saeki K, Yoshimoto T, *et al.* Repetitive monomorphic ventricular tachycardia of left coronary cusp origin. *Pacing Clin Electrophysiol* 1999;**22**:1553–1556.
96. Grimm W, Menz V, Hoffmann J, *et al.* Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia. *Pacing Clin Electrophysiol* 2001;**24**:166–171.
97. Buxton AE, Waxman HL, Marchlinski FE, *et al.* Right ventricular tachycardia: clinical and electrophysiologic characteristics. *Circulation* 1983;**68**:917–927.
98. Fung JW, Chan HC, Chan JY, *et al.* Ablation of nonsustained or hemodynamically unstable ventricular arrhythmia originating from the right ventricular outflow tract guided by noncontact mapping. *Pacing Clin Electrophysiol* 2003;**26**:1699–1705.
99. Nademanee K, Taylor R, Bailey WE, *et al.* Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. *Circulation* 2000;**102**:742–747.
100. Kowey PR, Marinchak RA, Rials SJ, *et al.* Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation. *Am J Cardiol* 1999;**84**:46R–51R.
101. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. *Circulation* 2000;**102**:I112–I118.
102. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 7: algorithm approach to ACLS emergencies: section 7A: principles and practice of ACLS. *Circulation* 2000;**102**:I136–I139.
103. Dorian P, Cass D. An overview of the management of electrical storm. *Can J Cardiol* 1997;**13**(Suppl A):13A–17A.
104. Bonow RO, Carabello B, Chatterjee K, *et al.* ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease). *J Am Coll Cardiol* 2006;**48**:e1–e148.
105. State-specific mortality from sudden cardiac death—United States, 1999. *MMWR Morb Mortal Wkly Rep* 2002;**51**:123–126.
106. Silka MJ, Hardy BG, Menashe VD, *et al.* A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. *J Am Coll Cardiol* 1998;**32**:245–251.
107. Oechslin EN, Harrison DA, Connelly MS, *et al.* Mode of death in adults with congenital heart disease. *Am J Cardiol* 2000;**86**:1111–1116.
108. Graham TP Jr., Bernard YD, Mellen BG, *et al.* Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. *J Am Coll Cardiol* 2000;**36**:255–261.
109. Alexander ME, Walsh EP, Saul JP, *et al.* Value of programmed ventricular stimulation in patients with congenital heart disease. *J Cardiovasc Electrophysiol* 1999;**10**:1033–1044.
110. Fish FA, Gillette PC, Benson DW Jr. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. *J Am Coll Cardiol* 1991;**18**:356–365.
111. Jonas M, Hod H. Is immunosuppressive treatment an option for myocarditis? *Isr J Med Sci* 1997;**33**:762–766.
112. Tai YT, Lau CP, Fong PC, *et al.* Incessant automatic ventricular tachycardia complicating acute coxsackie B myocarditis. *Cardiology* 1992;**80**:339–344.
113. Tubman TR, Craig B, Mulholland HC. Ventricular tachycardia associated with Coxsackie B4 virus infection. *Acta Paediatr Scand* 1990;**79**:572–575.
114. Gowrishankar K, Rajajee S. Varied manifestations of viral myocarditis. *Indian J Pediatr* 1994;**61**:75–80.
115. Mary AS, Hamilton M. Ventricular tachycardia in a patient with toxoplasmosis. *Br Heart J* 1973;**35**:349–352.
116. Etherington J, Salmon J, Ratcliffe G. Atrio-ventricular dissociation in meningococcal meningitis. *J R Army Med Corps* 1995;**141**:169–171.
117. Dhar KL, Adlakha A, Phillip PJ. Recurrent seizures and syncope, ventricular arrhythmias with reversible prolonged Q-Tc interval in typhoid myocarditis. *J Indian Med Assoc* 1987;**85**:336–337.
118. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. *Circulation* 1999;**99**:1091–1100.
119. Winkel E, Parrillo J. Myocarditis. *Curr Treat Options Cardiovasc Med* 2002;**4**:455–466.
120. Mayer W, Kleber FX, Wilske B, *et al.* Persistent atrioventricular block in Lyme borreliosis. *Klin Wochenschr* 1990;**68**:431–435.
121. Nagi KS, Thakur RK. Lyme carditis: indications for cardiac pacing. *Can J Cardiol* 1995;**11**:335–338.

122. Rassi A Jr., Rassi A, Little WC. Chagas' heart disease. *Clin Cardiol* 2000;23:883-889.
123. Muratore C, Rabinovich R, Iglesias R, et al. Implantable cardioverter defibrillators in patients with Chagas' disease: are they different from patients with coronary disease? *Pacing Clin Electrophysiol* 1997;20:194-197.
124. Malik JA, Hassan C, Khan GQ. Transient complete heart block complicating acute rheumatic fever. *Indian Heart J* 2002;54:91-92.
125. Liberman L, Hordof AJ, Alfayyadh M, et al. Torsade de pointes in a child with acute rheumatic fever. *J Pediatr* 2001;138:280-282.
126. Freed MS, Sacks P, Ellman MH. Ventricular tachycardia in acute rheumatic fever. *Arch Intern Med* 1985;145:1904-1905.
127. Wallace SM, Walton BI, Kharbanda RK, et al. Mortality from infective endocarditis: clinical predictors of outcome. *Heart* 2002;88:53-60.
128. Drenick EJ, Fislser JS. Sudden cardiac arrest in morbidly obese surgical patients unexplained after autopsy. *Am J Surg* 1988;155:720-726.
129. Sjostrom LV. Mortality of severely obese subjects. *Am J Clin Nutr* 1992;55:516S-523S.
130. Lattimore JD, Celermajor DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. *J Am Coll Cardiol* 2003;41:1429-1437.
131. Neumarker KJ. Mortality and sudden death in anorexia nervosa. *Int J Eat Disord* 1997;21:205-212.
132. Wyse DG, Friedman PL, Brodsky MA, et al. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. *J Am Coll Cardiol* 2001;38:1718-1724.
133. Kliegel A, Eisenburger P, Sterz F, et al. Survivors of ventricular tachyarrhythmias due to a transient or reversible disorder have a high recurrence rate of lethal cardiac events. *Resuscitation* 2002;54:237-243.
134. Brugada J, Aguinaga L, Mont L, et al. Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. *J Am Coll Cardiol* 2001;37:529-533.
135. Kelly P, Ruskin JN, Vlahakes GJ, et al. Surgical coronary revascularization in survivors of prehospital cardiac arrest: its effect on inducible ventricular arrhythmias and long-term survival. *J Am Coll Cardiol* 1990;15:267-273.
136. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. *N Engl J Med* 1994;331:1564-1575.
137. Di LA, Secoli G, Perkan A, et al. Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group. *Br Heart J* 1994;72:546-551.
138. Sugrue DD, Rodeheffer RJ, Codd MB, et al. The clinical course of idiopathic dilated cardiomyopathy. A population-based study. *Ann Intern Med* 1992;117:117-123.
139. Komajda M, Jais JP, Reeves F, et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. *Eur Heart J* 1990;11:824-831.
140. Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. *Circulation* 1989;80:1675-1680.
141. Kelly P, Coats A. Variation in mode of sudden cardiac death in patients with dilated cardiomyopathy. *Eur Heart J* 1997;18:879-880.
142. Tamburro P, Wilber D. Sudden death in idiopathic dilated cardiomyopathy. *Am Heart J* 1992;124:1035-1045.
143. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). *Lancet* 1994;344:493-498.
144. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. *N Engl J Med* 1995;333:77-82.
145. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation* 2000;101:1297-1302.
146. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). *Circulation* 2000;102:748-754.
147. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. *Eur Heart J* 2000;21:2071-2078.
148. Kadish A, Quigg R, Schaechter A, et al. Defibrillators in nonischemic cardiomyopathy treatment evaluation. *Pacing Clin Electrophysiol* 2000;23:338-343.
149. Grimm W, Alter P, Maisch B. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT. *Herz* 2004;29:348-352.
150. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J Med* 2004;350:2151-2158.
- 150a. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med* 2004;351:2481-2488.
151. Spirito P, Bellone P. Natural history of hypertrophic cardiomyopathy. *Br Heart J* 1994;72:S10-S12.
152. Louie EK, Edwards LC III. Hypertrophic cardiomyopathy. *Prog Cardiovasc Dis* 1994;36:275-308.
153. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. *Circulation* 1995;92:1680-1692.
154. DeRose JJ Jr., Banas JS Jr., Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. *Prog Cardiovasc Dis* 1994;36:475-484.
155. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). *N Engl J Med* 1987;316:844-852.
156. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). *N Engl J Med* 1987;316:780-789.
157. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. *Circulation* 1982;65:1388-1394.
158. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. *Circulation* 1997;96:2987-2991.
159. Mittal SR. Sudden cardiac death in hypertrophic cardiomyopathy: risk evaluation. *Int J Cardiol* 1995;52:1-4.
160. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. *N Engl J Med* 2000;342:1778-1785.
161. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. *J Am Coll Cardiol* 2003;42:1687-1713.
162. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. *N Engl J Med* 1997;336:775-785.
163. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. *J Am Coll Cardiol* 1990;15:1279-1285.
164. McKenna WJ, Harris L, Rowland E, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. *Am J Cardiol* 1984;54:802-810.
165. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. *N Engl J Med* 2000;342:365-373.
166. Maron BJ, Estes NA III, Maron MS, et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. *Circulation* 2003;107:2872-2875.
167. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. *J Am Coll Cardiol* 1997;30:1512-1520.
168. Schionning JD, Frederiksen P, Kristensen IB. Arrhythmogenic right ventricular dysplasia as a cause of sudden death. *Am J Forensic Med Pathol* 1997;18:345-348.
169. Munclinger MJ, Patel JJ, Mitha AS. Follow-up of patients with arrhythmogenic right ventricular cardiomyopathy dysplasia. *S Afr Med J* 2000;90:61-68.
170. Link MS, Wang PJ, Haugh CJ, et al. Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators. *J Interv Card Electrophysiol* 1997;1:41-48.
171. Hauer RN, Aliot E, Block M, et al. Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology. *Eur Heart J* 2001;22:1074-1081.
172. Myerburg RJ, Castellanos A. Clinical trials of implantable defibrillators. *N Engl J Med* 1997;337:1621-1623.

173. Corrado D, Leoni L, Link MS, *et al.* Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Circulation* 2003;**108**:3084–3091.
174. DeSilva RA. Central nervous system risk factors for sudden cardiac death. *Ann N Y Acad Sci* 1982;**382**:143–161.
175. Cox GF, Kunkel LM. Dystrophies and heart disease. *Curr Opin Cardiol* 1997;**12**:329–343.
176. Pelargonio G, Dello RA, Sanna T, *et al.* Myotonic dystrophy and the heart. *Heart* 2002;**88**:665–670.
177. Munoz J, Sanjuan R, Morell JS, *et al.* Ventricular tachycardia in Duchenne's muscular dystrophy. *Int J Cardiol* 1996;**54**:259–262.
178. Samuels MA. Neurally induced cardiac damage. Definition of the problem. *Neurol Clin* 1993;**11**:273–292.
179. Merino JL, Peinado R. Arrhythmias associated with neuromuscular disorders. *Card Electrophysiol Rev* 2002;**6**:132–135.
180. Becane HM, Bonne G, Varnous S, *et al.* High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. *Pacing Clin Electrophysiol* 2000;**23**:1661–1666.
181. Collieran JA, Hawley RJ, Pinnow EE, *et al.* Value of the electrocardiogram in determining cardiac events and mortality in myotonic dystrophy. *Am J Cardiol* 1997;**80**:1494–1497.
182. Corrado G, Lissone A, Beretta S, *et al.* Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. *Am J Cardiol* 2002;**89**:838–841.
183. Ducceschi V, Nigro G, Sarubbi B, *et al.* Autonomic nervous system imbalance and left ventricular systolic dysfunction as potential candidates for arrhythmogenesis in Becker muscular dystrophy. *Int J Cardiol* 1997;**59**:275–279.
184. Perloff JK, Stevenson WG, Roberts NK, *et al.* Cardiac involvement in myotonic muscular dystrophy (Steiner's disease): a prospective study of 25 patients. *Am J Cardiol* 1984;**54**:1074–1081.
185. Hiromasa S, Ikeda T, Kubota K, *et al.* Myotonic dystrophy: ambulatory electrocardiogram, electrophysiologic study, and echocardiographic evaluation. *Am Heart J* 1987;**113**:1482–1488.
186. Stevenson WG, Perloff JK, Weiss JN, *et al.* Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. *J Am Coll Cardiol* 1990;**15**:292–299.
187. James TN, Fisch C. Observations on the cardiovascular involvement in Friedreich's ataxia. *Am Heart J* 1963;**66**:164–175.
188. Roberts NK, Perloff JK, Kark RA. Cardiac conduction in the Kearns-Sayre syndrome (a neuromuscular disorder associated with progressive external ophthalmoplegia and pigmentary retinopathy). Report of 2 cases and review of 17 published cases. *Am J Cardiol* 1979;**44**:1396–1400.
189. Charles R, Holt S, Kay JM, *et al.* Myocardial ultrastructure and the development of atrioventricular block in Kearns-Sayre syndrome. *Circulation* 1981;**63**:214–219.
190. James TN. Observations on the cardiovascular involvement, including the cardiac conduction system, in progressive muscular dystrophy. *Am Heart J* 1962;**63**:48–56.
191. Bansch D, Antz M, Boczor S, *et al.* Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). *Circulation* 2002;**105**:1453–1458.
192. Strickberger SA, Hummel JD, Bartlett TG, *et al.* Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVERT. *J Am Coll Cardiol* 2003;**41**:1707–1712.
193. Cazeau S, Leclercq C, Lavergne T, *et al.* Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. *N Engl J Med* 2001;**344**:873–880.
194. Leon AR, Abraham WT, Curtis AB, *et al.* Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. *J Am Coll Cardiol* 2005;**46**:2348–2356.
195. Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). Available at: <http://www.ncbi.nlm.nih.gov/omim>. Accessed June 6, 2003.
196. Decision No. 1295/1999 EC of the European Parliament and of the Council of 29 April 1999. *Official Journal of the European Communities*; L155:1–5. Accessed June 22, 2003.
197. Moss AJ, Schwartz PJ, Crampton RS, *et al.* The long QT syndrome. Prospective longitudinal study of 328 families. *Circulation* 1991;**84**:1136–1144.
198. Kimbrough J, Moss AJ, Zareba W, *et al.* Clinical implications for affected parents and siblings of probands with long-QT syndrome. *Circulation* 2001;**104**:557–562.
199. Priori SG, Schwartz PJ, Napolitano C, *et al.* Risk stratification in the long-QT syndrome. *N Engl J Med* 2003;**348**:1866–1874.
200. Splawski I, Timothy KW, Sharpe LM, *et al.* Ca(V)_{1.2} calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell* 2004;**119**:19–31.
201. Marks ML, Whisler SL, Clericuzio C, *et al.* A new form of long QT syndrome associated with syndactyly. *J Am Coll Cardiol* 1995;**25**:59–64.
202. Moss AJ, Zareba W, Hall WJ, *et al.* Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. *Circulation* 2000;**101**:616–623.
203. Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. *J Am Coll Cardiol* 2005;**45**:1318–1321.
204. Napolitano C, Priori SG, Schwartz PJ, *et al.* Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. *JAMA* 2005;**294**:2975–2980.
205. Kannankeril PJ, Roden DM, Fish FA. Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen's syndrome. *J Cardiovasc Electrophysiol* 2004;**15**:119.
206. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. *J Am Coll Cardiol* 1992;**20**:1391–1396.
207. Alings M, Dekker L, Sadee A, *et al.* Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. *Pacing Clin Electrophysiol* 2001;**24**:1420–1422.
208. Mok NS, Chan NY, Chiu AC. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. *Pacing Clin Electrophysiol* 2004;**27**:821–823.
209. Maury P, Couderc P, Delay M, *et al.* Electrical storm in Brugada syndrome successfully treated using isoprenaline. *Europace* 2004;**6**:130–133.
210. Leenhardt A, Lucet V, Denjoy I, *et al.* Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. *Circulation* 1995;**91**:1512–1519.
211. Deal BJ, Miller SM, Scagliotti D, *et al.* Ventricular tachycardia in a young population without overt heart disease. *Circulation* 1986;**73**:1111–1118.
212. Proclemer A, Ciani R, Feruglio GA. Right ventricular tachycardia with left bundle branch block and inferior axis morphology: clinical and arrhythmological characteristics in 15 patients. *Pacing Clin Electrophysiol* 1989;**12**:977–989.
213. Mehta D, Odawara H, Ward DE, *et al.* Echocardiographic and histologic evaluation of the right ventricle in ventricular tachycardias of left bundle branch block morphology without overt cardiac abnormality. *Am J Cardiol* 1989;**63**:939–944.
214. Morady F, Kadish AH, DiCarlo L, *et al.* Long-term results of catheter ablation of idiopathic right ventricular tachycardia. *Circulation* 1990;**82**:2093–2099.
215. O'Connor BK, Case CL, Sokoloski MC, *et al.* Radiofrequency catheter ablation of right ventricular outflow tachycardia in children and adolescents. *J Am Coll Cardiol* 1996;**27**:869–874.
216. Movsowitz C, Schwartzman D, Callans DJ, *et al.* Idiopathic right ventricular outflow tract tachycardia: narrowing the anatomic location for successful ablation. *Am Heart J* 1996;**131**:930–936.
217. Lerman BB, Belardinelli L, West GA, *et al.* Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. *Circulation* 1986;**74**:270–280.
218. Lerman BB. Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. *Circulation* 1993;**87**:382–390.
219. Wilber DJ, Baerman J, Olshansky B, *et al.* Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation. *Circulation* 1993;**87**:126–134.
220. Lemery R, Brugada P, Bella PD, *et al.* Nonischemic ventricular tachycardia. Clinical course and long-term follow-up in patients without clinically overt heart disease. *Circulation* 1989;**79**:990–999.

221. Goy JJ, Tauxe F, Fromer M, Schlapfer J, Vogt P, Kappenberger L. Ten-year follow-up of 20 patients with idiopathic ventricular tachycardia. *Pacing Clin Electrophysiol* 1990;13:1142-1147.
222. Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. *Am Heart J* 2002;144:e10.
223. Mont L, Seixas T, Brugada P, et al. Clinical and electrophysiologic characteristics of exercise-related idiopathic ventricular tachycardia. *Am J Cardiol* 1991;68:897-900.
224. Hayashi H, Fujiki A, Tani M, et al. Circadian variation of idiopathic ventricular tachycardia originating from right ventricular outflow tract. *Am J Cardiol* 1999;84:99-101.
225. Gill JS, Blaszyk K, Ward DE, et al. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. *Am Heart J* 1993;126:1126-1133.
226. Davidson S, Surawicz B. Ectopic beats and atrioventricular conduction disturbances. In patients with hypopotassemia. *Arch Intern Med* 1967;120:280-285.
227. Hollifield JW. Thiazide treatment of hypertension. Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy. *Am J Med* 1986;80:8-12.
228. Hollifield JW. Thiazide treatment of systemic hypertension: effects on serum magnesium and ventricular ectopic activity. *Am J Cardiol* 1989;63:22G-25G.
229. Podrid PJ. Potassium and ventricular arrhythmias. *Am J Cardiol* 1990;65:33E-44E.
230. Dyckner T, Helmers C, Wester PO. Cardiac dysrhythmias in patients with acute myocardial infarction. Relation to serum potassium level and prior diuretic therapy. *Acta Med Scand* 1984;216:127-132.
231. Nordrehaug JE, von der Lippe G. Hypokalaemia and ventricular fibrillation in acute myocardial infarction. *Br Heart J* 1983;50:525-529.
232. Nordrehaug JE, Johannessen KA, von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. *Circulation* 1985;71:645-649.
233. Kafka H, Langevin L, Armstrong PW. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. *Arch Intern Med* 1987;147:465-469.
234. Hulting J. In-hospital ventricular fibrillation and its relation to serum potassium. *Acta Med Scand Suppl* 1981;647:109-116.
235. Thompson RG, Cobb LA. Hypokalemia after resuscitation from out-of-hospital ventricular fibrillation. *JAMA* 1982;248:2860-2863.
236. Glass JD, McQuillen EN, Hardin NJ. Iatrogenic cardiac herniation: post mortem case. *J Trauma* 1984;24:632-633.
237. Chadda KD, Lichstein E, Gupta P. Hypomagnesemia and refractory cardiac arrhythmia in a nondigitalized patient. *Am J Cardiol* 1973;31:98-100.
238. Tzivoni D, Keren A, Cohen AM, et al. Magnesium therapy for torsades de pointes. *Am J Cardiol* 1984;53:528-530.
239. Solomon RJ. Ventricular arrhythmias in patients with myocardial infarction and ischaemia. Relationship to serum potassium and magnesium. *Drugs* 1984;28(Suppl 1):66-76.
240. Sjogren A, Edvinsson L, Fallgren B. Magnesium deficiency in coronary artery disease and cardiac arrhythmias. *J Intern Med* 1989;226:213-222.
241. Rasmussen HS, McNair P, Norregard P, et al. Intravenous magnesium in acute myocardial infarction. *Lancet* 1986;1:234-236.
242. Abraham AS, Rosenmann D, Kramer M, et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. *Arch Intern Med* 1987;147:753-755.
243. Rasmussen HS, Suenson M, McNair P, et al. Magnesium infusion reduces the incidence of arrhythmias in acute myocardial infarction. A double-blind placebo-controlled study. *Clin Cardiol* 1987;10:351-356.
244. Smith LF, Heagerty AM, Bing RF, et al. Intravenous infusion of magnesium sulphate after acute myocardial infarction: effects on arrhythmias and mortality. *Int J Cardiol* 1986;12:175-183.
245. Hollifield JW. Magnesium depletion, diuretics, and arrhythmias. *Am J Med* 1987;82:30-37.
246. Rajs J, Rajs E, Lundman T. Unexpected death in patients suffering from eating disorders. A medico-legal study. *Acta Psychiatr Scand* 1986;74:587-596.
247. Iseri LT, Freed J, Bures AR. Magnesium deficiency and cardiac disorders. *Am J Med* 1975;58:837-846.
248. Zwerling HK. Does exogenous magnesium suppress myocardial irritability and tachyarrhythmias in the nondigitalized patient? *Am Heart J* 1987;113:1046-1053.
249. Spies CD, Sander M, Stangl K, et al. Effects of alcohol on the heart. *Curr Opin Crit Care* 2001;7:337-343.
250. Albert CM, Manson JE, Cook NR, et al. Moderate alcohol consumption and the risk of sudden cardiac death among U.S. male physicians. *Circulation* 1999;100:944-950.
251. Dyer AR, Stamler J, Paul O, et al. Alcohol consumption, cardiovascular risk factors, and mortality in two Chicago epidemiologic studies. *Circulation* 1977;56:1067-1074.
252. Wannamethee G, Shaper AG. Alcohol and sudden cardiac death. *Br Heart J* 1992;68:443-448.
253. Ettinger PO, Wu CF, De La Cruz C Jr., et al. Arrhythmias and the 'Holiday Heart': alcohol-associated cardiac rhythm disorders. *Am Heart J* 1978;95:555-562.
254. Chenet L, McKee M, Leon D, et al. Alcohol and cardiovascular mortality in Moscow: new evidence of a causal association. *J Epidemiol Community Health* 1998;52:772-774.
255. Chenet L, Britton A, Kalediene R, et al. Daily variations in deaths in Lithuania: the possible contribution of binge drinking. *Int J Epidemiol* 2001;30:743-748.
256. Shkolnikov VM, McKee M, Chervyakov VV, et al. Is the link between alcohol and cardiovascular death among young Russian men attributable to misclassification of acute alcohol intoxication? Evidence from the city of Izhevsk. *J Epidemiol Community Health* 2002;56:171-174.
257. Wannamethee G, Shaper AG, Macfarlane PW, et al. Risk factors for sudden cardiac death in middle-aged British men. *Circulation* 1995;91:1749-1756.
258. Sexton PT, Walsh J, Jamrozik K, et al. Risk factors for sudden unexpected cardiac death in Tasmanian men. *Aust N Z J Med* 1997;27:45-50.
259. Jouven X, Desnos M, Guerot C, et al. Predicting sudden death in the population: the Paris Prospective Study I. *Circulation* 1999;99:1978-1983.
260. Escobedo LG, Caspersen CJ. Risk factors for sudden coronary death in the United States. *Epidemiology* 1997;8:175-180.
261. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. *J Am Coll Cardiol* 1985;5:141B-149B.
262. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995;333:1301-1307.
263. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998;279:1615-1622.
264. Jouven X, Charles MA, Desnos M, et al. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. *Circulation* 2001;104:756-761.
265. Fuller CM, McNulty CM, Spring DA, et al. Prospective screening of 5,615 high school athletes for risk of sudden cardiac death. *Med Sci Sports Exerc* 1997;29:1131-1138.
266. Fuller CM. Cost effectiveness analysis of screening of high school athletes for risk of sudden cardiac death. *Med Sci Sports Exerc* 2000;32:887-890.
267. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. *J Womens Health* 1998;7:547-557.
268. Widerhorn J, Widerhorn AL, Rahimtoola SH, et al. WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. *Am Heart J* 1992;123:796-798.
269. Tawam M, Levine J, Mendelson M, et al. Effect of pregnancy on paroxysmal supraventricular tachycardia. *Am J Cardiol* 1993;72:838-840.
270. Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. *Am J Cardiol* 1995;76:675-678.
271. Brodsky M, Doria R, Allen B, et al. New-onset ventricular tachycardia during pregnancy. *Am Heart J* 1992;123:933-941.
272. Gowda RM, Khan IA, Mehta NJ, et al. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. *Int J Cardiol* 2003;88:129-133.
273. Aronow WS. Treatment of ventricular arrhythmias in older adults. *J Am Geriatr Soc* 1995;43:688-695.
274. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone

- Myocardial Infarction Arrhythmia Trial Investigators. *Lancet* 1997;**349**: 675-682.
275. Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population: detection by 24-hour ambulatory electrocardiography. *Chest* 1982;**81**:302-307.
276. Lee KL, Tai YT. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety. *Clin Cardiol* 1997;**20**:372-377.
277. Aronow WS, Ahn C, Mercando AD, et al. Prevalence and association of ventricular tachycardia and complex ventricular arrhythmias with new coronary events in older men and women with and without cardiovascular disease. *J Gerontol A Biol Sci Med Sci* 2002;**57**:M178-M180.
278. Volpi A, Cavalli A, Turato R, et al. Incidence and short-term prognosis of late sustained ventricular tachycardia after myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-3) Data Base. *Am Heart J* 2001;**142**:87-92.
279. Kannel WB, Cupples LA, D'Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. *Am Heart J* 1987;**113**: 799-804.
280. Kuller L, Lilienfeld A, Fisher R. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease. *Circulation* 1966;**34**:1056-1068.
281. Geelen P, Lorga FA, Primo J, et al. Experience with implantable cardioverter defibrillator therapy in elderly patients. *Eur Heart J* 1997;**18**:1339-1342.
282. Panotopoulos PT, Axtell K, Anderson AJ, et al. Efficacy of the implantable cardioverter-defibrillator in the elderly. *J Am Coll Cardiol* 1997;**29**:556-560.
283. Saksena S, Mathew P, Giorgberidze I, et al. Implantable defibrillator therapy for the elderly. *Am J Geriatr Cardiol* 1998;**7**:11-13.
284. Silka MJ, Kron J, Dunnigan A, et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. *Circulation* 1993;**87**:800-807.
285. Sellers TD Jr., Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. *Circulation* 1977;**56**: 260-267.
286. Garson A Jr, Gillette PC, Titus JL, et al. Surgical treatment of ventricular tachycardia in infants. *N Engl J Med* 1984;**310**:1443-1445.
287. Davis AM, Gow RM, McCrindle BW, et al. Clinical spectrum, therapeutic management, and follow-up of ventricular tachycardia in infants and young children. *Am Heart J* 1996;**131**:186-191.
288. Pfammatter JP, Paul T. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical profile and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. *J Am Coll Cardiol* 1999;**33**:2067-2072.
289. Roden DM, Anderson ME. Proarrhythmia. In Kass RS, Clancey CE, eds. *Handbook of Experimental Pharmacology: vol. 171. Basis and Treatment of Cardiac Arrhythmias*. Boston, MA: Springer Verlag; 2006. p 288-304.
290. Antman EM, Wenger TL, Butler VP Jr., et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. *Circulation* 1990;**81**: 1744-1752.
291. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. *Science* 2002;**297**: 1333-1336.
292. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. *Circulation* 2002;**105**:1943-1948.
293. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. *Circulation* 1988;**77**:392-397.
294. Roden DM. Drug-induced prolongation of the QT interval. *N Engl J Med* 2004;**350**:1013-1022.
295. Bajaj AK, Woosley RL, Roden DM. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. *Circulation* 1989;**80**:994-1002.
296. Chouty F, Funck-Brentano C, Landau JM, et al. Efficacy of high doses of molar lactate by the venous route in flecainide poisoning. *Presse Med* 1987;**16**:808-810.
297. Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. *Circulation* 1989;**80**:1571-1579.
298. Tada H, Sticherling C, Oral H, et al. Brugada syndrome mimicked by tricyclic antidepressant overdose. *J Cardiovasc Electrophysiol* 2001;**12**:275.
299. Hoffman JR, Votey SR, Bayer M, et al. Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. *Am J Emerg Med* 1993;**11**:336-341.
300. Lipschultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. *N Engl J Med* 1995;**332**:1738-1743.
301. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6 to 19 years after anthracycline therapy: a series of 15 patients. *Med Pediatr Oncol* 1995;**24**:352-361.
302. Ferrari E, Benhamou M, Baudouy M. Cardiotoxicity associated with trastuzumab (herceptin). An undesired effect leads towards a model of cardiac insufficiency. *Arch Mal Coeur Vaiss* 2004;**97**:333-337.
303. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. *Breast* 2004;**13**:173-183.
304. Pichon MF, Cvitkovic F, Hacene K, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. *In Vivo* 2005;**19**:567-576.
305. Bu'Lock FA, Mott MG, Oakhill A, et al. Early identification of anthracycline cardiomyopathy: possibilities and implications. *Arch Dis Child* 1996;**75**:416-422.
306. Li CK, Sung RY, Kwok KL, et al. A longitudinal study of cardiac function in children with cancer over 40 months. *Pediatr Hematol Oncol* 2000;**17**:77-83.
307. De WD, Suys B, Maurus R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. *Pediatr Res* 1996;**39**:504-512.
308. Klewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. *J Am Coll Cardiol* 1992;**19**:394-401.
309. Lenk MK, Zeybek C, Okutan V, et al. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography. *Turk J Pediatr* 1998;**40**:373-383.
310. Johnson GL, Moffett CB, Geil JD, et al. Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring. *J Pediatr Hematol Oncol* 1996;**18**:72-75.
311. Postma A, Elzenga NJ, Haaksma J, et al. Cardiac status in bone tumor survivors up to nearly 19 years after treatment with doxorubicin: a longitudinal study 1. *Med Pediatr Oncol* 2002;**39**:86-92.
312. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. *Cancer* 1993;**71**:493-509.